Know What's Happening in Pharma
Know What's Happening in Pharma
Pharma Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Shionogi completes $2.5B acquisition of ALS drug Radicava
Shionogi has finalized a $2.5 billion purchase of global rights to the ALS therapy Radicava from Tanabe Pharma, adding a rare‑disease asset and a U.S. commercial platform that is expected to generate roughly $700 million in revenue starting fiscal 2026.
Also developing:
By the numbers: Lupin Limited acquires VISUfarma in undisclosed deal
Wake Forest School of Medicine has started a five‑year, $5.7 million NIH‑funded MORPH trial to evaluate a low‑impact “movement medicine” protocol for seniors with osteoarthritis. The remote program uses wearables, mobile apps and weekly video groups to encourage frequent, gentle activity throughout the day. Researchers hope the approach will shift how biohackers and clinicians address age‑related musculoskeletal decline.
Semaglutide and tirzepatide have shown a 20% drop in major cardiovascular events, a 24% slowdown in kidney disease progression, and a 33% lower Alzheimer’s diagnosis rate. The FDA’s expanded Wegovy label and a wave of new brain‑health trials are turning...
Rosen Law Firm has filed a securities‑fraud class action against gene‑therapy company REGENXBIO, alleging false statements about its RGX-111 candidate. Investors who bought shares between Feb. 9 2022 and Jan. 27 2026 must file by April 14 2026 to serve as lead plaintiff.
A new adrenal gland organoid accurately models human development and hormone production, offering a platform to study stress responses, disease mechanisms, and potential regenerative therapies for adrenal disorders. biotechnology
Therapy resistance remains a major hurdle in prostate cancer, especially after initial success with hormone‑based treatments. The Deng Lab at Yale School of Medicine is dedicated to uncovering the molecular mechanisms that enable cancer cells to evade therapy. The team combines...
SPRY Therapeutics (ARS Pharmaceuticals) received FDA approval on April 3 to remove age limits on its Neffy 1mg needle‑free epinephrine nasal spray, allowing use by anyone weighing 33 lb or more. The move opens the product to a broader pediatric and...
Prilenia Therapeutics and Ferrer have opened enrollment for the PREVAiLS Phase 3 trial of pridopidine, a sigma‑1 receptor agonist, marking the only currently recruiting confirmatory study in amyotrophic lateral sclerosis. The trial will involve up to 500 participants across 60...
Longevity treatments for a 91-year-old. That's the kind of story that captures where Silicon Valley's immortality bet is actually heading. Great piece by @AmyDMarcus, who I had the chance to meet in Boston recently. She brings serious depth to this beat,...
A new study in the British Journal of Cancer identifies a molecular triad—nuclear fibroblast growth factor‑2 (FGF2), androgen receptor (AR), and Wnt pathway activation—that defines a targetable subset of antiprogestin‑resistant luminal breast cancer. The researchers demonstrated that nuclear FGF2 cooperates...
K.C. Pharmaceuticals voluntarily recalled 3,111,072 bottles of over‑the‑counter eye drops sold at CVS, Walgreens, Kroger and other chains after the FDA identified a lack of assurance of sterility. The FDA classified the action as a Class II recall, prompting retailers to...
Life is a marshmallow test. Incretin modulators help you win while staying happy. I often ask big audiences - "how many of you are on GLP1?" and only a couple hands go up. Sometimes, none. That's when I understood that...
One observation here: GLP-1s are priced at maybe 25-50x production cost (not counting R&D). LLM usage is priced at perhaps 1x inference cost (not counting training). In any case, two great innovations that are rapidly catching on.
A three‑year Korean trial of 3,000 patients with atherosclerotic disease found that aiming for an LDL‑cholesterol level below 55 mg/dL reduced major heart attacks, strokes and deaths by about a third compared with the conventional 70 mg/dL goal. Researchers say the result...
This is great to see. Biotech and pharma competition with China is going to force us to sharpen and accelerate processes in the US, and cut red tape. And we'll get the benefit of Chinese drugs as well. Win/win.
A potential universal flu shot? Intranasal EV vaccine protected mice from H5N1, H7N9 https://t.co/WroXpi6YP3 https://t.co/umAPlnRjbF
They ported the 5-MeO-DMT pathway from the Sonoran Desert toad into tobacco plants and then used AlphaFold3 to debug the protein structure, leading to a 40x yield increase. Prompt psychedelic design.
